# Selank FAQ — Common questions about the research record > Answers to common questions about Selank (TKPRPGP): mechanism, GAD trial results, comparison with benzodiazepines, BDNF effects, regulatory status, and the limits of existing research. Direct answers drawn from the published literature. Every quantitative claim links to a primary source. ## Questions and answers **What is Selank and how is it different from tuftsin?** Selank (TKPRPGP) is a synthetic heptapeptide developed at the Institute of Molecular Genetics in Moscow. Its starting point is tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from the Fc region of immunoglobulin G that functions as an endogenous immunomodulator. Selank extends tuftsin by adding a Pro-Gly-Pro tripeptide at the C-terminus. That three-residue addition was purposeful: it substantially improves metabolic stability by resisting the tissue peptidases that rapidly cleave native tuftsin in blood and plasma. The result is a molecule with tuftsin's structural core but a significantly longer window of biological activity — and a pharmacological profile that expanded well beyond tuftsin's primarily immunological role [18]. --- **What does the research say about Selank's effect on generalized anxiety disorder?** Two published human studies address GAD specifically. In a 62-patient RCT, Selank produced anxiolytic effects equivalent to medazepam (a benzodiazepine) on the Hamilton Anxiety and Zung scales, and additionally showed antiasthenic and mild psychostimulant effects not seen in the benzodiazepine arm [6]. In a 20-patient study using 2700 microg/day intranasally, 40% of participants experienced rapid HARS reduction (from 20.3 to 7.0) within 1-3 days, and the remaining 60% achieved similar clinical response (HARS from 16.1 to 6.2) by day 14 [7]. Both studies are limited by their single-center Russian origin and small sample sizes. --- **How does Selank work in the brain — what are its mechanisms?** The research literature identifies five overlapping mechanisms. (1) Selank acts as a positive allosteric modulator of GABA-A receptors, enhancing GABA's own effect at a site distinct from the benzodiazepine binding site [1]. (2) It inhibits enkephalinase enzymes that degrade endogenous opioid peptides (enkephalins), prolonging their activity [2]. (3) It upregulates BDNF expression in hippocampal and prefrontal cortical tissue [3]. (4) It acutely elevates serotonin turnover in the hypothalamus and brainstem [14]. (5) Under stress conditions, it suppresses pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha) [10]. No single mechanism is likely to account for the full behavioral profile — the multi-target convergence appears to be the point. --- **What doses of Selank have been studied in animals and humans?** In rodent studies, 0.3 mg/kg (300 microg/kg) by intraperitoneal or intranasal route is the most consistently used dose across anxiety, memory, withdrawal, and monoamine studies [4, 8, 9, 14]. In the human clinical record, 2700 microg/day intranasally (as nine individual 300 microg doses per day) is the most precisely documented dose [7]. The dose used in the 62-patient medazepam comparison trial is not reported in the available abstract [6]. --- **Does research suggest Selank is habit-forming like benzodiazepines?** The existing preclinical data does not show tolerance or withdrawal signs at research doses, and the mechanism offers a plausible explanation: Selank's GABA-A interaction occurs at a distinct binding site from benzodiazepines, with different subtype selectivity [1]. In the ethanol-withdrawal model, Selank did not reduce voluntary ethanol consumption in alcohol-preferring rats, suggesting it addressed withdrawal anxiety without reinforcing the underlying preference [9]. That said, no long-term (beyond one month) safety studies in animals or humans have been published. The absence of published tolerance data means the question has not been rigorously tested, not that it has been definitively answered in the negative. --- **What is the evidence for Selank's effect on BDNF and memory?** Three studies document this connection. Inozemtseva et al. (2008) showed intranasal Selank regulates BDNF mRNA and protein levels in the rat hippocampus in vivo [3]. Kolik et al. (2019) found that 0.3 mg/kg/day for 7 days prevented ethanol-induced BDNF elevation in hippocampus and frontal cortex during withdrawal, while protecting against the associated memory impairment [4]. Semenova et al. (2010) linked Selank's memory-consolidation effect to serotonin turnover elevation — when given during the consolidation phase of a conditioned task, it enhanced 30-day memory retention [14]. The BDNF and serotonergic mechanisms may both contribute to the nootropic profile. --- **Has Selank been compared to diazepam or medazepam in research?** Yes, in two experimental contexts. The 62-patient RCT compared intranasal Selank directly to oral medazepam in GAD/neurasthenia patients; the two drugs produced equivalent Hamilton and Zung scale reductions [6]. In a rat chronic mild stress model, Selank (300 microg/kg/day intranasal) and diazepam (1 mg/kg/day oral) were compared alone and in combination over 14 days. Selank alone and diazepam alone each reduced anxiety, but neither fully normalized behavior to pre-stress baseline. The combination of both normalized anxiety completely [5]. This additive effect is consistent with different binding sites on the GABA-A receptor. --- **Why was Selank developed in Russia and what is its regulatory status?** Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, the same institution that developed Semax (a related nootropic heptapeptide). Russia has a long research tradition in synthetic peptide pharmacology — the Institute of Molecular Genetics and the Zakusov Research Institute of Pharmacology have been the primary sources of the published Selank literature since the early 1990s. In Russia, Selank is registered as a prescription nasal spray (trade name Selanc) for GAD and neurasthenia — the only approved medical use anywhere in the world. In the United States and EU, Selank is not approved for any indication and is classified as a research chemical. It is not specifically named on the WADA Prohibited List but may fall under the S0 non-approved substances category. --- **What do cytokine studies of Selank show about its immune effects?** Two studies document Selank's effects on inflammatory cytokines. Yasenyavskaya et al. (2021) found that 20 days of Selank (100 microg/kg/day, i.p.) under chronic social stress in rats significantly reduced IL-1beta, IL-6, TNF-alpha, and TGF-beta1 toward control baseline while restoring IL-4 [10]. Uchakina et al. (2008) found that Selank at 10(-7) M completely suppressed IL-6 gene expression in peripheral blood lymphocytes from depressed patients in cell culture, and a 14-day in vivo course shifted the Th1/Th2 cytokine balance in anxiety-asthenic patients [17]. Whether these immunological effects are independent of the anxiolytic mechanism or are causally related remains an open question. --- **What are the limitations of existing Selank research?** Four limitations stand out. First, all human clinical data comes from Russian research institutes — no independent international replication has been published. Second, the clinical sample sizes (n=20-62) are preliminary by current regulatory standards. Third, no published pharmacokinetic study reports Selank's human half-life, Cmax, or bioavailability after nasal spray administration. Fourth, strain-dependent effects in mice (BALB/c vs C57BL/6 showing opposite responses to naloxone pretreatment) raise genuine questions about inter-individual variability that cannot yet be predicted in human subjects. --- **Is Selank the same as Semax?** No. Semax (MEHFPGP) is a separate synthetic heptapeptide derived from ACTH rather than tuftsin, also developed at the Institute of Molecular Genetics. Both are nootropic/anxiolytic peptides with enkephalinase inhibitory activity — Zozulya et al. (2001) notes that Semax similarly inhibits enkephalin-degrading enzymes [2]. In the Russian research literature, both peptides are sometimes described as complementary: Selank primarily anxiolytic, Semax primarily cognitive-stimulant. They are chemically distinct molecules with distinct structural origins and distinct pharmacological profiles. --- **What is the Hamilton Anxiety Rating Scale (HARS) and how is it used in Selank studies?** The Hamilton Anxiety Rating Scale (also called HAM-A) is a 14-item clinician-administered scale used to quantify anxiety symptom severity in clinical research. Scores range from 0 to 56; higher scores indicate greater anxiety. In the Syunyakov et al. (2012) GAD study, rapid responders started at a mean HARS of 20.3 (moderate anxiety) and fell to 7.0 (minimal anxiety) within 1-3 days [7]. Conventional responders started at a mean of 16.1 and fell to 6.2 by day 14 [7]. A reduction to below approximately 7-8 is generally considered clinical response in the anxiolytic literature. The Zozulia et al. (2008) study also used HARS as a primary endpoint, showing equivalent scores between Selank and medazepam at trial completion [6]. --- **Does Selank show strain-dependent effects in animal models?** Yes, and this is one of the more scientifically interesting features of the preclinical record. Vasil'eva et al. (2016) found that anxiolytic and nootropic behavioral effects appeared exclusively in BALB/c mice, not in C57BL/6 mice, at the same dose and route [12]. Kozlovskii et al. (2012) found that naloxone pretreatment blocked Selank's anxiolytic effect in BALB/c but paradoxically enhanced it in C57BL/6 [13]. Narkevich et al. (2008) found that dopamine metabolite responses to Selank were strain-opposite: elevated in C57BL/6 hippocampus, reduced in BALB/C [15]. These strain-level differences likely reflect baseline differences in GABA-A receptor subtype expression, opioid system tone, and baseline anxiety phenotype between the two strains — and they raise a legitimate translational question about whether individual humans with different anxiety-system baselines might respond to Selank differently. --- **What is the significance of the biphasic gene expression pattern Selank produces?** Volkova et al. (2016) found that intranasal Selank (300 microg/kg) in Wistar rats produced significant changes in mRNA levels of 45 genes in the frontal cortex within 1 hour, including dramatic downregulation of GABA receptor subunit genes (Gabre, Gabrq) and the orexin gene (Hcrt) [16]. By 3 hours, the pattern reversed — Hcrt mRNA increased 128-fold. The 1-hour Selank and GABA patterns correlated positively (r=0.86), then diverged to negative correlation (r=-0.39) at 3 hours. This biphasic time course — initial suppression followed by rebound — distinguishes Selank's downstream genomic signature from GABA itself and implies that Selank is not simply mimicking GABAergic tone but triggering a regulatory sequence that GABA alone does not initiate. --- An organized reading of the Selank research record — mechanisms and clinical findings reported as the studies measured them, the single-region evidence base and its genuine limits named plainly, and no clinical or commercial service implied.